RT Journal Article
SR Electronic
T1 Systematic investigations of COVID-19 in 283 cancer patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20083246
DO 10.1101/2020.04.28.20083246
A1 Wang, Jie
A1 Song, Qibin
A1 Chen, Yuan
A1 Wang, Zhijie
A1 Chu, Qian
A1 Gong, Hongyun
A1 Cai, Shangli
A1 Dong, Xiaorong
A1 Xu, Bin
A1 Hu, Weidong
A1 Wang, Qun
A1 Li, Linjun
A1 Yang, Jiyuan
A1 Xie, Zhibin
A1 Luo, Zhiguo
A1 Liu, Jing
A1 Luo, Xiuli
A1 Ren, Jie
A1 Rao, Zhiguo
A1 Xu, Xinhua
A1 Pan, Dongfeng
A1 Hu, Zuowei
A1 Feng, Gang
A1 Hu, Chiding
A1 Luo, Liqiong
A1 Lu, Hongda
A1 Ran, Ruizhi
A1 Jin, Jun
A1 Xu, Yanhua
A1 Yang, Yong
A1 Zhang, Zhihong
A1 Kuang, Li
A1 Wang, Runkun
A1 Dong, Youhong
A1 Sun, Jianhai
A1 Hu, Wenbing
A1 Yi, Tienan
A1 Wu, Hanlin
A1 Liu, Mingyu
A1 Xu, Jiachen
A1 Duan, Jianchun
A1 Zhao, Zhengyi
A1 Wang, Guoqiang
A1 Xu, Yu
A1 He, Jie
YR 2020
UL http://medrxiv.org/content/early/2020/05/03/2020.04.28.20083246.abstract
AB Background Cancer patients are considered to be highly susceptible to viral infections, however, the comprehensive features of COVID-19 in these patients remained largely unknown. The present study aimed to assess the clinical characteristics and outcomes of COVID-19 in a large cohort of cancer patients.Design, Setting, and Participants Data of consecutive cancer patients admitted to 33 designated hospitals for COVID-19 in Hubei province, China from December 17, 2019 to March 18, 2020 were retrospectively collected. The follow-up cutoff date was April 02, 2020. The clinical course and survival status of the cancer patients with COVID-19 were measured, and the potential risk factors of severe events and death were assessed through univariable and multivariable analyses.Results A total of 283 laboratory confirmed COVID-19 patients (50% male; median age, 63.0 years [IQR, 55.0 to 70.0]) with more than 20 cancer types were included. The overall mortality rate was 18% (50/283), and the median hospitalization stay for the survivors was 26 days. Amongst all, 76 (27%) were former cancer patients with curative resections for over five years without recurrence. The current cancer patients exhibited worse outcomes versus former cancer patients (overall survival, HR=2.45, 95%CI 1.10 to 5.44, log-rank p=0.02; mortality rate, 21% vs 9%). Of the 207 current cancer patients, 95 (46%) have received recent anti-tumor treatment, and the highest mortality rate was observed in the patients receiving recent chemotherapy (33%), followed by surgery (26%), other anti-tumor treatments (19%), and no anti-tumor treatment (15%). In addition, a higher mortality rate was observed in patients with lymphohematopoietic malignancies (LHM) (53%, 9/17), and all seven LHM patients with recent chemotherapy died. Multivariable analysis indicated that LHM (p=0.001) was one of the independent factors associating with critical illness or death.Conclusions This is the first systematic study comprehensively depicting COVID-19 in a large cancer cohort. Patients with tumors, especially LHM, may have poorer prognosis of COVID-19. Additional cares are warranted and non-emergency anti-tumor treatment should be cautiously used for these patients under the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the CAMS Initiative for Innovative Medicine (CAMS 2020-I2M-CoV19-004). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author on reasonable request.